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Background: Glucocorticoids (GCs) cause apoptosis in malignant cells of lymphoid lineage by transcriptionally
regulating a plethora of genes. As a result, GCs are included in almost all treatment protocols for lymphoid
malignancies, particularly childhood acute lymphoblastic leukemia (chALL). The most commonly used synthetic
GCs in the clinical setting are prednisolone and dexamethasone. While the latter has a higher activity and more
effectively reduces the tumor load in patients, it is also accompanied by more serious adverse effects than the
former. Whether this difference might be explained by regulation of different genes by the two GCs has never
been addressed.
Results: Using a recently developed GC bioassay based on a GC-responsive reporter construct in human Jurkat
T-ALL cells, we found ~7-fold higher biological activity with dexamethasone than prednisolone. Similarly, 1.0e-7 M
dexamethasone and 7.0e-7 M prednisolone triggered similar cell death rates in CCRF-CEM-C7H2 T-chALL cells after
72 hours of treatment. Using microarray-based whole genome expression profiling and a variety of statistical and
other approaches, we compared the transcriptional response of chALL cells to 6 hour exposure to both synthetic
GCs at the above concentrations. Our experiments did not detect any gene whose regulation by dexamethasone
differed significantly from that by prednisolone.
Conclusions: Our findings suggest that the reported differences in treatment efficacy and cytotoxicity of
dexamethasone and prednisolone are not caused by inherent differences of the 2 drugs to regulate the expression
of certain genes, but rather result either from applying them in biologically in-equivalent concentrations and/or
from differences in their pharmacokinetics and - dynamics resulting in different bioactivities in tumor cells and
normal tissues.
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Acute lymphoblastic leukemia (ALL) is a rapidly-de-
veloping aggressive cancer of white blood cells that
starts in the bone marrow [1], and is the most prevalent
pediatric cancer [2]. Glucocorticoids (GCs) cause mas-
sive cell death and cell cycle arrest in malignant cells
from the lymphoid lineage and are therefore included in* Correspondence: johannes.rainer@i-med.ac.at
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article, unless otherwise stated.almost all treatment protocols for lymphoid malig-
nancies, particularly childhood acute lymphoblastic leu-
kemia (chALL) [2]. GCs exert their effects through their
cognate receptor, the GC-receptor (GR, encoded by the
gene NR3C1). The GR is a ligand-activated zinc finger
transcription factor of the nuclear receptor family [3]
that resides in the cytoplasm and, upon ligand binding,
translocates into the nucleus, where it modulates ex-
pression of its target gene either by binding to GC-re-
sponsive elements in the gene promoters/enhancers or
by protein-protein interactions with other transcription
factors [4].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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thetic GCs, mostly prednisolone (PRED), but also dexa-
methasone (DEX), during various phases of therapy in
combination with chemotherapeutic drugs, resulting in a
cure rate of up to ~90% [2,5]. The most commonly used
GC in chALL is PRED, the active metabolite of prednisone
[6]. In the past several years, DEX has been increasingly
used for chALL treatment, specifically in a delayed in-
tensification phase of current treatment protocols [7] that
result in lower bone marrow and CNS relapse rates, but
also increased adverse effects. DEX differs molecularly
from PRED only by a fluorine atom at the 9α position of
ring B and a methyl group at position C16 of ring D. DEX
has enhanced lymphoblast cytotoxicity and CNS penetra-
tion capability, the latter being crucial to successful ALL
therapy since, despite the good outcome of contemporary
childhood ALL treatments, CNS relapses remain a chal-
lenge [6]. Treatment of the CNS is considered a quantum
leap forward in improving the overall survival of chALL
patients [8]. Pharmacokinetic investigations showed that
the shorter half-life of PRED (60 minutes for PRED vs.
200 minutes for DEX, biological half-lives 24–36 vs. 36–
54 hours [9]) affects its protein-binding properties and
might reduce the duration of leukemic cell exposure to
cytotoxic concentrations in the cerebrospinal fluid, com-
promising its effectiveness [6,10]. Moreover, the DEX-GR
complex is thought to be more stable than the PRED-GR
complex, and the GR seems to have a greater affinity for
DEX than PRED in leukemic cells [11]. Generally, DEX
seems to be the more active corticosteroid in the treat-
ment of ALL [12,13], and many studies reported increased
event-free survival and significantly decreased risk of CNS
relapses with DEX vs. PRED [5-7].
However, these improvements are also associated with
increased toxicity of DEX. Specifically, a symptomatic
osteonecrosis that disproportionately affects adolescent
chALL patients has been correlated with continuous
DEX treatment in the delayed intensification phase [14].
Lowering the effective DEX concentration by alternative
week rather than continuous treatment in a 21 day-long
delayed intensification phase has been shown to sig-
nificantly reduce osteonecrosis among high risk chALL
patients (specifically those over 16 years of age) [14].
Analysis of DEX and PRED data from the literature is
complicated due to heterogeneity of treatment regimens,
dose ratios and study populations. Teuffel et al. [15] re-
cently published a meta-analysis comparing the efficacy
and toxicity of both synthetic GCs in the induction
phase of chALL therapy in an effort to account for the
above mentioned complications. While DEX has been
shown to be more effective than PRED in lowering CNS
and bone marrow relapses, it was also significantly asso-
ciated with death during induction, neuro-psychiatric
adverse events and myopathy.Although many clinical studies comparing the effects
of PRED and DEX have been conducted, to our know-
ledge, the differences between the two GCs have not
been investigated on a molecular level. This study, there-
fore, focused on determining whether these differences
might be explained by differences in the transcriptional
responses of chALL cells to treatment with the 2 syn-
thetic GCs at comparable biological activities.
Results
Bioactivity of dexamethasone and prednisolone
Comparison of the transcriptional responses to the two
synthetic GCs requires treatment of the cells in bio-
equivalent concentrations of the two agents. The com-
monly used concentration of DEX in in vitro studies is
1.0e-7 M [16,17]. To determine an equivalent PRED con-
centration, we treated T-chALL CCRF-CEM-C7H2 cells
in three independent experiments with 1.0e-7 M DEX and
5.0e-7 M, 7.0e-7 M and 9.0e-7 M PRED concentrations.
Ethanol-treated cells served as empty carrier controls.
GC-bioactivity levels were recorded in all experiments
after 6 and 24 hours of treatment in the cell supernatants
using our recently established GC-bioactivity assay (GBA)
[18]. The GBA measures GC activity using a reporter con-
struct containing GR binding sites, thus directly determi-
ning the transcriptional activity of the ligand-activated
GR. In addition, cells were harvested after 24, 48 and
72 hours, treated with propidium iodide (PI) and sub-
jected to FACS analysis to determine the percentage of
cells undergoing cell death. GC-bioactivity levels remained
constant over time for all GCs/concentrations, suggesting
a long half-life of PRED and DEX (Figure 1, upper panel).
From all PRED concentrations used, 7.0e-7 M yielded the
closest GC-bioactivity to 1.0e-7 M (see Figure 1, upper
panel) and was thus selected as the DEX-equivalent PRED
concentration. Cell death induction was observed for
all GC concentrations, with rates surpassing 80% after
72 hours in all instances. Interestingly, however, cell death
rates of all PRED concentrations were slightly lower after
48 hours than those of 1.0e-7 M DEX.
To determine whether the GC activity of these con-
centrations is achievable in children given the standard
scheduling and dosing of the drugs we measured the GC
bioactivity in serum samples of 8 childhood B-ALL pa-
tients taken prior to and 6 and 24 hours after initiation
of the systemic GC mono-therapy. The administered
prednisolone resulted in GC bioactivities equivalent to
that of 1.0e-7 M DEX (see Additional file 1: Figure S2),
showing that the in vitro used concentrations are indeed
pharmacologically relevant.
Taken together, 7.0e-7 M PRED resulted in about the
same GC bioactivity as 1.0e-7 M DEX and had a similar
potency to induce cell death in ALL cells (Figure 1,
lower panel).
Figure 1 GC bioactivity and GC-induced apoptosis. Upper panel: GC-bioactivity in cell supernatants of dexamethasone (rectangles) and
prednisolone (circles) for the indicated time points and concentrations. Shown are mean and standard deviations from 3 independent experiments.
Lower panel: Percentages (mean and standard deviation from 3 independent experiments) of dead cells after exposure to DEX or PRED at the
indicated time points.
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and PRED
We next investigated whether the response of ALL cells
exposed to either synthetic GC differed at the trans-
criptional level by generating a microarray data set with
RNA extracted from cells of the above experiments, i.e.,
from CCRF-CEM-C7H2 cells treated for 6 hours with
1.0e-7 M dexamethasone, 7.0e-7 M prednisolone (the
DEX-equivalent prednisolone concentration determined
above) or 0.1% ethanol as empty carrier control. Thus
the data set consisted of a total of 9 Affymetrix Gene ST
1.0 GeneChips with 3 biological replicates for each con-
dition. Even though cell death occurs considerably later
(see Figure 1) we selected the 6 hours time point, be-
cause we were particularly interested in the early ini-
tiation of transcriptional response ultimately leading to
cell death. Also, most of the GC-regulated genes after
6 hours are potential direct GR target genes, as sug-
gested by the presence of GR binding sites in their pro-
moter/enhancer regions [17].
First, we directly compared the PRED- and DEX-treated
samples. Gene-wise tests for differential regulation were
conducted as paired tests based on the observation of
different apoptosis rates between the experiments (see
Additional file 1: Figure S3). Criteria for significant diffe-
rences in all comparisons were an adjusted p-value < 0.05
and an absolute M-value (log2 fold-change) > 1. Genes
passing these criteria were more than two-fold regulated
at a 5% false discovery rate (FDR). In this analysis, not a
single gene was found significantly differently regulatedbetween PRED and DEX treated samples (Figure 2A).
Thus, using this approach, there was no significant diffe-
rence in the transcriptional response of C7H2 ALL cells
after exposure to either of the 2 synthetic GCs.
In an alternative approach, we correlated the average
M-values for DEX and PRED treatment, determined by
comparisons of GC- to ethanol-exposed cells and repre-
senting GC-regulation of all genes by either synthetic
GC. A high correlation of GC-regulations was observed
(R = 0.84, Additional file 1: Figure S4) that was even higher
when only genes found to be significantly regulated by
one of the two GCs using the above cut-off criteria
(R = 0.98, Figure 2B) were considered. The slope of the
linear regression line fit to the PRED versus DEX data was
0.81, suggesting that the overall response was slightly
stronger (~1.2 fold) in DEX- compared to PRED-treated
samples (see Figure 2B). This observation is in good agree-
ment with the slightly lower GC-bioactivity measured for
7.0e-7 M PRED (see Figure 1), and also with the slightly
lower cell death rates after 48 hours (Figure 1B). Thus,
this alternative approach further supported the notion that
both drugs regulate the same genes.
Finally, we applied an approach that is frequently used
but, as mentioned below and detailed in the Supplement,
has significant inherent problems. This analysis com-
pares genes found to be significantly regulated by either
treatment. Again, we used paired statistics to test for sig-
nificance of differential expression between GC-treated
and control samples and applied the above cut-off cri-
teria to define genes as being either DEX- or PRED-
Figure 2 Direct comparison of the transcriptional responses to DEX and PRED exposure. A: Volcano plot showing the difference in GC
regulation (M, i.e. log2 fold-change) for each gene against its significance (−log10 of the p-values adjusted for multiple hypothesis testing)
between 6 hours prednisolone (PRED) or dexamethasone (DEX) treatments. The grey-dashed horizontal line represents the significance cut-off
(5% FDR), the dashed vertical lines the cut-off for the extent of regulation (two-fold difference). Points are colored according to the local point
density. B: Correlation of M-values representing the extent of gene regulation by DEX or PRED treatment. Shown are genes identified to be
significantly regulated by either DEX or PRED treatment. The grey-dashed and the solid black line represent the identity line and the linear
regression fit to the data, respectively.
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peared to be quite remarkable differences, i.e., 93 PRED-
regulated versus 295 DEX-regulated genes (see Additional
file 1: Figure S6). However, as detailed in the supplement,
this difference probably resulted from technical and/or
analytical issues. Thus, the M- and/or p-values for 181 of
the 208 genes found to be significantly regulated by only
one of the two GCs were just below the cut-off for the
other GC (see also Figure 3). A heatmap representing the
results of a hierarchical cluster analysis on the per-
experiment M-values of the above genes also showed that
DEX-regulated genes are concordantly regulated by PRED
and vice versa, albeit to a slightly lower extent (see
Additional file 1: Figure S7). Therefore, such genes cannot
be considered “unregulated” by the respective GC. These
“borderline regulations” might be explained (at least in−2 0 2 4 6
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tration used (Figure 1 upper panel and Figure 2B) and the
higher inter-replicate variance in the PRED-treated cells
(see Additional file 1: Figure S5), resulting in lower signifi-
cance levels. The remaining 21 genes corresponded quite
well to the expected number of false positives (5% FDR
for 295 genes = ~15). To test this possibility, we analyzed
a completely independent set of microarrays with RNA
from C7H2 cells treated for 6 hours in 3 independent
experiments with either 1.0e-7 M DEX, 4.0 or 8.0e-6 M
Solu-dacortin (a water soluble form of prednisolone) or
0.1% ethanol. In this data set, 17 of the 21 genes were
not significantly regulated by DEX (see Additional file 1:
Table S4). Two of the remaining 4 genes were also regu-
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The increasing up-regulation of this gene with in-
creasing GC concentrations along with the increasing
bioactivity measured by the GBA for higher PRED con-
centrations (Figure 1) suggested a dosage dependency of
the transcriptional response to GCs. Summarizing, this
elaborate analysis provided no evidence that DEX and
PRED regulated different genes, and also clearly high-
lighted the problems of this type of microarray data
analysis.
We next evaluated the GC-regulation of the GR (NR3C1)
and of known GR target genes TSC22D3 (also known as
GILZ), FKBP5, RCAN1, SOCS1 and DDIT4 [17,19-21]. All
of these genes were significantly and strongly up-regulated
by DEX and by PRED (see Additional file 1: Table S5). The
extent of up-regulation was highly similar which further
suggests that the employed concentrations result in
equivalent transcriptional activities.
In conclusion, the combined data strongly suggest that
DEX and PRED regulated the same genes, at least in the
investigated chALL cell line model.
Discussion
This report addressed the clinically and biologically rele-
vant question of whether the observed differences in cli-
nical outcomes in chALL patients treated with either DEX
or PRED might be explained by a difference in the genes
regulated by either synthetic GC. Such a difference could
result from the fact that different ligands might generate
distinct platforms on the GR for interaction with co-
regulatory proteins, as has been suggested for numerous
“discriminatory” GR ligands that may mediate gene regu-
lation via transactivation rather than transrepression orFigure 4 GC-regulation of IL6ST. Shown are mean M-values (log2-fold ch
PRED-treated CCRF-CEM-C7H2 cells in the indicated concentrations, represe
triplicates in 3 independent experiments.vice versa (for review see [22]). If so, the differentially reg-
ulated genes could be easily identified in an approach such
as ours, which might then lead to novel therapeutic mea-
sures directed at manipulating the respective pathways.
However, our comprehensive analysis did not identify any
significant differences in the transcriptional response of
ALL cells to treatment with either synthetic GC. Thus,
our findings strongly suggest that the differential effects of
the 2 synthetic GCs, at least with regard to their efficacy,
do not result from differences in gene regulations. The in-
creased efficacy of DEX over PRED may rather result from
applying PRED at lower biological activity, better transfer
of DEX through the blood–brain barrier [6], a longer
half-life time of DEX [9] or other differences in pharmaco-
kinetics and/or pharmacodynamics. Concerning adverse
effects, our study cannot provide a corresponding conclu-
sive answer because these effects primarily result from the
effect of GCs on other tissues in the body that have not
been investigated. Given that the same genes are regulated
in the chALL cell system analyzed here, it seems unlikely
that the transcriptional response to treatment with the 2
GCs differs in other tissues although this possibility has
not been formally ruled out.
Interestingly, from a more technical point of view, while
DEX- and PRED-treated cells showed no significant dif-
ferences in gene regulations (Figure 2A), and correlation
of M-values failed to reveal differences in the trans-
criptional response of ALL cells to either synthetic GC
(Figure 2B), the responses seemed to differ when compa-
ring genes defined as significantly GC-regulated by each
individual GC (Additional file 1: Figure S6). However, this
apparent difference was misleading: as we demonstrated,
such an approach to compare transcriptional responses,ange values) and standard deviations for 6 or 24 hours DEX and
nting GC-regulation of IL6ST measured by real time RT-PCR in
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which is based simply on the significantly-regulated genes,
is highly problematic because of its strong dependency on
the defined hard cut-off criteria for gene regulation and
on properties of the data set itself, such as inter-replicate
variances. In our setting, the slightly weaker bioactivity of
the PRED concentration used and the higher inter-repli-
cate variance in the PRED samples resulted in a lower
number of significantly regulated genes compared to DEX
treatment. More thorough analysis of the genes found to
be significantly regulated only by DEX revealed that the
differences were either quantitative or corresponded to
false positives. Thus, comparison of actual gene regulation
values by both treatments using statistical approaches and
correlation of these M-values are clearly superior in such
a setting since they directly compare gene regulations
caused by treatment with either synthetic GC.
Conclusions
In this study, we compared the transcriptional response of
childhood T-ALL cells to treatment with the synthetic
GCs prednisolone and dexamethasone. Based on data
from a total of 21 microarrays and real-time RT-PCR-
based verifications, we observed no significant differences
in responses, and concluded that both GCs regulate the
same genes in chALL cells. The slightly weaker response
of PRED-treated cells was probably caused by the slightly
lower activity of 7.0e-7 M PRED compared to 1.0e-7
M DEX.
Our findings suggest that the reported differences in
treatment efficacy and cytotoxicity of dexamethasone and
prednisolone are not caused by inherent differences of the
2 drugs to regulate the expression of certain genes, but
rather result either from applying them in biologically in-
equivalent concentrations and/or from differences in their
pharmacokinetics and -dynamics resulting in different bio-
activities in tumor cells and normal tissues.
Methods
Cell system and GC-treatment
We used the GC-sensitive C7H2 sub-clone of the exten-
sively studied childhood T-ALL cell line CCRF-CEM
[23-26] to evaluate GC-activity, apoptosis induction and
gene regulations induced by dexamethasone or predni-
solone treatment. Cells were kept in culture in RPMI 1640
supplemented with 10% fetal calf serum and 2 mM L-glu-
tamine at 37°C, 5% CO2 and saturated humidity. For gene
expression profiling, apoptosis determination and GC-
bioactivity experiments, the cells were cultured in the
presence of 1.0e-7 M dexamethasone and varying concen-
trations of prednisolone, i.e. 5.0, 7.0 and 9.0e-7 M (with
7.0e-7 M of PRED being used for gene expression profil-
ing). Both GCs were solved in ethanol, thus, cells treated
with 0.1% of ethanol were used as empty carrier controls.In additional experiments, C7H2 cells were treated with
1.0e-7 M dexamethasone, 2.0, 4.0, 6.0 and 8.0 e-6 M Solu-
dacortin [prednisolone 21-(sodium succinate), a water-
soluble prednisolone], and 2.0, 4.0 and 6.0 e-7 M Dexabene
[dexamethasone 21-(disodium phosphate); a water-soluble
dexamethasone]. GC-bioactivity was measured after 6, 24
and 48 hours of treatment, and cell death induction after
24, 48 and 72 hours. To determine in vivo GC bioactivity
of PRED during systemic GC mono-therapy we performed
GBA measurements on serum samples of previously pub-
lished GC-treated patients with childhood ALL [16].
Cell death determinations
Apoptosis was determined by fluorescence-activated cell
sorter (FACS) analyses of propidium iodide (PI)-treated
permeabilized cells, as previously detailed [27]. In brief,
cells were analyzed with a FACScan cytometer (Becton
Dickinson Biosciences, San Jose, CA) to acquire forward
scatter/sideward scatter and FL-2 (log scale). In FL-2, the
percentage of nuclei with reduced DNA-content (sub-G1
peak) was assessed and reported as percentage of dead
cells.
GC bioactivity measurements
Activity of the administered GCs was estimated using
our recently-developed GC bioactivity assay (GBA) [18],
which measures transcriptional activity of the GR upon
GC-treatment using a reporter construct containing a
known GR binding site. Aliquots of 9.0e4 cells contai-
ning the reporter construct in 100 μL culture medium
were supplemented either with a log2 step DEX dilution
series in 25 μL of culture medium as standard or with
25 μL of supernatant from the DEX- and PRED-treated
cells in their respective concentrations. These samples
were plated in 96-well plates and incubated at 37°C and
5% CO2 in a humidified incubator. After an incubation
of 6 hours, mean Venus nuclear protein (VNP) activity
was determined analyzing 20,000 events and measuring
mean fluorescence in the FL-2 channel with a FACScan
cytometer. Cell debris was removed from the analysis.
Mean VNP activity values from samples with unknown
GC bioactivity were fit to the linear part of the VNP
values from the standard curve by dilution and the cor-
responding GC-activity (expressed in DEX equivalents)
was reported.
Microarray data set generation and pre-processing
Microarray data generation was performed according to
the manufacturer’s protocols. In brief, total cell RNA was
extracted using the TRIZOL protocol, and RNA quantity
and integrity was determined by optical density measure-
ments and the 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA), respectively. Two hundred and fifty ng
of high quality RNA was processed using the Ambion
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Ambion) and the Affymetrix GeneChip WT Terminal
Labeling Kit (Affymetrix). The resulting biotinylated tar-
gets were hybridized in an Affymetrix hybridization oven
to a total of 9 Affymetrix Human Gene ST 1.0 GeneChips.
The microarrays were washed and stained in an Affmetrix
fluidic station 450 and fluorescence signals were recorded
in an Affymetrix scanner 3000. All further analysis was
performed in R (version 3.0.2) using packages from the
Bioconductor project ([28], version 2.13). The raw micro-
array data was pre-processed using the “generalgcrma”
package [17] and our custom transcript-level “CEL defi-
nition file” (CDF) that defines probe sets for each tran-
script of all genes defined in the Ensembl database version
74. Generation of the CDF package for the analysis is
similar to that reported by Rainer and colleagues [17] ex-
cept that the 25 nt long probe sequences were aligned
against the cDNA sequences and sequences of non-
coding transcripts. The CDF defined a total of 125,709
transcript probe sets for 25,426 genes. After GCRMA [29]
pre-processing, a representative transcript probe set was
selected for each gene. Similar to the study of Aneichyk
et al. [30], transcript probe sets were preferred consisting
of more than 9 probes and with high average expression
and variance in expression across all 9 samples.
Generation and pre-processing of the second microarray
data set of 12 Affymetrix Human Gene ST microarrays
with RNA from C7H2 cells treated with 6 hours 1.0e-7 M
DEX, 4.0 and 8.0e-6 M Solu-dacortin, and 6 hours of
ethanol treatment was performed analogously except that
for cRNA cleanup of the 3 GeneChips for 8.0e-6 M
Solu-dacortin treatment, the Affymetrix GeneChip 3′ IVT
Expression Kit was used.
Raw and pre-processed microarray data has been depo-
sited at the Gene Expression Omnibus (Accession number
GSE55878).
Differential expression analysis
For differential expression analysis, we used the mo-
derated t-test implemented in Bioconductor’s limma
package [31] and subsequently adjusted the obtained
p-values using the multiple hypotheses testing correction
method of Benjamini and Hochberg (BH) [32] for strong
control of the false discovery rate (FDR). Based on the
observation that apoptosis rates differed between ex-
periments after 24 and 48 hours (see Additional file 1:
Figure S3), we included a categorical variable repre-
senting the experiment assignment of the sample into
the linear regression model used for the differential ex-
pression analysis, rendering the resulting tests equivalent
to paired tests. To assess differences in transcriptional re-
sponses, we directly compared PRED- and DEX-treated
samples. To identify genes significantly regulated by each
synthetic GC, we compared DEX- and PRED-treatedsamples to the empty carrier controls (ethanol-treated
samples).
We considered genes with an adjusted p-value smaller
than 0.05 and an absolute M-value (log2 fold-change) or
difference in M-values greater than 1 as significantly dif-
ferentially expressed or regulated. This cut-off controls
the false discovery rate (FDR) at 5% and additionally
requires at least a 2-fold regulation (or difference in
regulation) of a gene.
Real-time RT-PCR
Samples were taken at the time points indicated in the text
and subjected to AB Taqman-based real-time RT-PCR simi-
lar to that reported by Mansha et al. [33] using the following
assays: TBP: Hs00427620_m1, IL6ST: Hs01006739_m1 (de-
tecting all RefSeq and most GenBank mRNAs of IL6ST).
Measurements were performed in the same RNA sam-
ples used for microarray-based gene expression profiling.
CT values of three technical replicates were averaged and
normalized against the housekeeping gene TATA-box
binding protein (TBP). Normalized measurements (ΔCT)
of the 3 biological replicates were averaged and the dif-
ference between GC-treated and control samples were re-
ported as M-values (log2-fold change values, −ΔΔCT).
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article (and its additional files). Raw and
pre-processed microarray data is available at the Gene
Expression Omnibus with accession numbers GSE55877
(main data set) and GSE55876 (additional data set with
cells exposed to Solu-dacortin, a water soluble form of
PRED) and GSE55878 for the full series.
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Additional file 1: Supplementary Figures and Tables.
Abbreviations
chALL: Childhood acute lymphoblastic leukemia; CNS: Central nervous
system; DEX: Dexamethasone; GBA: Glucocorticoid bioactivity assay;
GC: Glucocorticoid; FDR: False discovery rate; PI: Propidium iodide;
PRED: Prednisolone; VNP: Venus nuclear protein.
Competing interests
The authors declare that they have no have competing interests.
Authors’ contributions
DB and SE performed the microarray data analysis. DB analyzed the GBA and
apoptosis data. BG and AK performed the GBA and apoptosis assays, and the
microarray experiments. SE, RK and JR wrote the manuscript and JR and RK
planned the experiments. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Martina Brunner and Armin Kofler for technical assistance. This
work was supported by the Austrian Science Fund (MCBO). SE is supported by a
fellowship from La Caixa. The Tyrolean Cancer Research Institute is supported by
the Tiroler Krankenanstalten Ges.m.b.H (TILAK), the Tyrolean Cancer Aid Society,
various businesses, financial institutions, and the people of Tyrol.
Bindreither et al. BMC Genomics 2014, 15:662 Page 8 of 8
http://www.biomedcentral.com/1471-2164/15/662Author details
1Division of Molecular Pathophysiology, Biocenter, Medical University
Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria. 2Structural Biology and
Biocomputing Program, Spanish National Cancer Research Center (CNIO),
Madrid, Spain. 3Tyrolean Cancer Research Institute, Innrain 66, 6020
Innsbruck, Austria.
Received: 30 April 2014 Accepted: 4 August 2014
Published: 7 August 2014References
1. Stanulla M, Schrappe M: Treatment of childhood acute lymphoblastic
leukemia. Semin Hematol 2009, 46:52–63.
2. Pui C-H, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet 2008,
371:1030–1043.
3. Laudet V, Gronemeyer H: The Nuclear Receptor Factsbook. London, UK:
Academic Press; 2002.
4. Kassel O, Herrlich P: Crosstalk between the glucocorticoid receptor and
other transcription factors: molecular aspects. Mol Cell Endocrinol 2007,
275:13–29.
5. Inaba H, Greaves M, Mullighan CG: Acute lymphoblastic leukaemia.
Lancet 2013, 381:1943–1955.
6. Inaba H, Pui C-H: Glucocorticoid use in acute lymphoblastic leukaemia.
Lancet Oncol 2010, 11:1096–1106.
7. McNeer JL, Nachman JB: The optimal use of steroids in paediatric acute
lymphoblastic leukaemia: no easy answers. Br J Haematol 2010,
149:638–652.
8. Norris RE, Adamson PC: Challenges and opportunities in childhood cancer
drug development. Nat Rev Cancer 2012, 12:776–782.
9. Meikle AW, Tyler FH: Potency and duration of action of glucocorticoids.
Effects of hydrocortisone, prednisone and dexamethasone on human
pituitary-adrenal function. Am J Med 1977, 63:200–207.
10. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG: Differences in
cerebrospinal fluid penetration of corticosteroids: possible relationship
to the prevention of meningeal leukemia. J Clin Oncol 1987, 5:202–207.
11. Iacobelli S, Natoli V, Longo P, Ranelletti FO, De Rossi G, Pasqualetti D,
Mandelli F, Mastrangelo R: Glucocorticoid receptor determinations in
leukemia patients using cytosol and whole-cell assays. Cancer Res 1981,
41:3979–3984.
12. Kaspers GJ, Kaspers GJL, Veerman AJP, Veerman AJ, Popp-Snijders C, Lomecky
M, Van Zantwijk CH, Swinkels LM, Swinkels LMJW, Van Wering ER, Pieters R:
Comparison of the antileukemic activity in vitro of dexamethasone and
prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol
1996, 27:114–121.
13. Cantrill HL, Waltman SR, Palmberg PF, Zink HA, Becker B: In vitro
determination of relative corticosteroid potency. J Clin Endocrinol Metab
1975, 40:1073–1077.
14. Mattano LA, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG,
Gaynon PS, Seibel NL, Children’s Oncology Group: Effect of alternate-week
versus continuous dexamethasone scheduling on the risk of osteonecrosis
in paediatric patients with acute lymphoblastic leukaemia: results from the
CCG-1961 randomised cohort trial. Lancet Oncol 2012, 13:906–915.
15. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier M-C, Shah PS, Beyene
J, Sung L: Dexamethasone versus prednisone for induction therapy in
childhood acute lymphoblastic leukemia: a systematic review and
meta-analysis. Leukemia 2011, 25:1232–1238.
16. Schmidt S, Rainer J, Riml S, Ploner C, Jesacher S, Achmüller C, Presul E,
Skvortsov S, Crazzolara R, Fiegl M, Raivio T, Jänne OA, Geley S, Meister B,
Kofler R: Identification of glucocorticoid-response genes in children with
acute lymphoblastic leukemia. Blood 2006, 107:2061–2069.
17. Rainer J, Lelong J, Bindreither D, Mantinger C, Ploner C, Geley S, Kofler R:
Research resource: transcriptional response to glucocorticoids in childhood
acute lymphoblastic leukemia. Mol Endocrinol 2012, 26:178–193.
18. Oppl B, Kofler A, Schwarz S, Rainer J, Kofler R: Establishing a sensitive and
specific assay for determination of glucocorticoid bioactivity. Wien Klin
Wochenschr 2011, 123:222–229.
19. Cannarile L, Zollo O, D’Adamio F, Ayroldi E, Marchetti C, Tabilio A, Bruscoli S,
Riccardi C: Cloning, chromosomal assignment and tissue distribution of
human GILZ, a glucocorticoid hormone-induced gene. Cell Death Differ
2001, 8:201–203.20. U M, Shen L, Oshida T, Miyauchi J, Yamada M, Miyashita T: Identification of
novel direct transcriptional targets of glucocorticoid receptor. Leukemia
2004, 18:1850–1856.
21. Hirakawa Y, Nary L, Medh R: Glucocorticoid evoked upregulation of
RCAN1-1 in human leukemic CEM cells susceptible to apoptosis. J Mol
Signal 2009, 4:6.
22. Kumar R, McEwan IJ: Allosteric modulators of steroid hormone receptors:
structural dynamics and gene regulation. Endocr Rev 2012, 33:271–299.
23. Strasser-Wozak EM, Hattmannstorfer R, Hála M, Hartmann BL, Fiegl M, Geley
S, Kofler R: Splice site mutation in the glucocorticoid receptor gene
causes resistance to glucocorticoid-induced apoptosis in a human acute
leukemic cell line. Cancer Res 1995, 55:348–353.
24. Thompson EB, Johnson BH: Regulation of a distinctive set of genes in
glucocorticoid-evoked apoptosis in CEM human lymphoid cells. Recent
Prog Horm Res 2003, 58:175–197.
25. Lambrou GI, Vlahopoulos S, Papathanasiou C, Papanikolaou M, Karpusas M,
Zoumakis E, Tzortzatou-Stathopoulou F: Prednisolone exerts late mitogenic
and biphasic effects on resistant acute lymphoblastic leukemia cells:
Relation to early gene expression. Leuk Res 2009, 33:1684–1695.
26. Laane E, Panaretakis T, Pokrovskaja K, Buentke E, Corcoran M, Söderhäll S,
Heyman M, Mazur J, Zhivotovsky B, Porwit A, Grandér D: Dexamethasone-
induced apoptosis in acute lymphoblastic leukemia involves differential
regulation of Bcl-2 family members. Haematologica 2007, 92:1460–1469.
27. Geley S, Hartmann BL, Hattmannstorfer R, Löffler M, Ausserlechner MJ,
Bernhard D, Sgonc R, Strasser-Wozak EM, Ebner M, Auer B, Kofler R:
p53-induced apoptosis in the human T-ALL cell line CCRF-CEM.
Oncogene 1997, 15:2429–2437.
28. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R,
Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney
L, Yang JYH, Zhang J: Bioconductor: open software development for
computational biology and bioinformatics. Genome Biol 2004, 5:R80.
29. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F: A model-based
background adjustment for oligonucleotide expression arrays. J Am Stat
Assoc 2004, 99:909–917.
30. Aneichyk T, Bindreither D, Mantinger C, Grazio D, Goetsch K, Kofler R, Rainer
J: Translational profiling in childhood acute lymphoblastic leukemia: no
evidence for glucocorticoid regulation of mRNA translation. BMC
Genomics 2013, 14:844.
31. Smyth GK: Linear models and empirical Bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol
2004, 3(Art. 3):29 (electronic).
32. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995,
57:289–300.
33. Mansha M, Carlet M, Ploner C, Gruber G, Wasim M, Wiegers GJ, Rainer J,
Geley S, Kofler R: Functional analyses of Src-like adaptor (SLA), a
glucocorticoid-regulated gene in acute lymphoblastic leukemia. Leuk Res
2010, 34:529–534.
doi:10.1186/1471-2164-15-662
Cite this article as: Bindreither et al.: The synthetic glucocorticoids
prednisolone and dexamethasone regulate the same genes in acute
lymphoblastic leukemia cells. BMC Genomics 2014 15:662.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
